Register Login

AURA BIOSCIENCES, INC. (AURA)

(90% Positive) AURA BIOSCIENCES, INC. (AURA) Announces Enrollment Update for potential Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Aug. 11, 2026, 11:07 a.m.

    📋 AURA BIOSCIENCES, INC. (AURA) - Clinical Trial Update

    Filing Date: 2026-08-11

    Accepted: 2026-08-11 07:05:26

    Event Type: Clinical Trial Update

    Event Details:

    AURA BIOSCIENCES, INC. (AURA) Announces Clinical Trial Update AURA BIOSCIENCES, INC. (AURA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: potential, results
    • Diseases/Conditions: next stage of growth BOSTON
    • Clinical Stage: Phase 3
    • Collaboration: NMIBC
      • sar in ocular oncology Interim NMIBC data reinforce bel
      • sar’s potential for durable efficacy and favorable safety profile; NMIBC program being strategically deprioritized to focus company resources on ocular oncology Organizational restructuring and disciplined capital allocation strategy to align with ocular oncology focus extend expected cash runway into 1H 2029 Strengthening leadership team with appointments of experienced industry executives as Chief Operating Officer, Chief Regulatory and Quality Officer, and Chief People Officer to position Aura for next stage of growth BOSTON, MA – August 11, 2026 – Aura Biosciences, Inc. (NASDAQ: AURA), a clinical
      • stage biotechnology company developing a potentially transformative first Management Commentary: '"Completing enrollment in our Phase 3 CoMpass trial of bel-sar for early choroidal melanoma positions us well for the next phase of our company’s evolution to become a leading ocular oncology company," said Natalie Holles'

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: AURA BIOSCIENCES, INC.
    • Ticker Symbol: AURA

Search

News categories